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Abstract
Background: Vitiligo is a chronic depigmented skin disorder with regional melanocytes depletion. The pathogenesis was
not completely clarified. Recently, more and more evidence suggested that polymorphisms of some genes are associated
with vitiligo risk. Here, we want to examine the association between the inducible nitric oxide synthase (iNOS) gene
polymorphisms and the risk of vitiligo in Chinese populations.
Methods and Principal Findings: In a hospital-based case-control study of 749 patients with vitiligo and 763 age- and sex-
matched healthy controls, three polymorphisms of iNOS gene were genotyped by using the PCR-restriction fragment length
polymorphism (PCR-RFLP) and mutagenically separated PCR (MS-PCR) methods, respectively. We found the iNOS-954
polymorphism was associated with a significantly higher risk of vitiligo (adjusted OR=1.36, 95% CI=1.02–1.81).
Furthermore, this association is more pronounced in vulgaris vitiligo, active vitiligo and vitiligo without other autoimmune
diseases in the stratification study. Analysis of haplotypes showed increased risk for the C-1173C-954CEx16+14 (OR=1.44, 95%
CI=1.01–1.74). In addition, the serum iNOS activity is significantly associated with iNOS-954 combined genotype (GC+CC)
and is much higher in vitiligo patients than in the controls (P,0.01). Logistic regression analysis of iNOS activity showed
increased risk between higher activity and iNOS-954 GRC variant genotype carriers (Ptrend,0.001).
Conclusions and Significance: INOS gene polymorphisms may play an important role in the genetic susceptibility to the
development of vitiligo.
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Introduction
Vitiligo is an acquired depigmentary disorder characterized by
the appearance of white patches resulting from the loss of
functional melanocytes and melanin from the skin and mucous. It
affects 0.1–2% of the world population [1] without preference for
a specific gender [2]. Several theories about the pathomechanism
of vitiligo have been suggested, including: autoimmune, neural,
radical, self destruction and inherent defect theories [3]. However,
none of them can explain the pathomechanism of vitiligo perfectly.
Nitric oxide (NO), a short-lived, free radical gas, act as an
intercellular messenger in most or all mammalian organs, playing
a major role in diverse physiologic processes and pathologic
conditions [4,5]. Many studies suggest that NO is involved in the
inhibition of cell proliferation, differentiation, and apoptosis and,
thus, may contribute to the pathogenesis of various autoimmune
diseases [2,6,7]. NO is synthesized by a group of enzymes called
NO synthase (NOS). NOS catalyses the production of NO and L-
citrulline from L-arginine, O2 and NADPH. NOS family consists
of three isoforms: neuronal NOS (nNOS), endothelial NOS
(eNOS), and inducible NOS (iNOS) [8,9,10,11]. ENOS and
nNOS produce NO within seconds and its activities are direct and
short acting, whereas iNOS produces very large, toxic amounts of
NO in a sustained manner. Expression of iNOS is under the
regulation of several cytokines such as interferon gamma (IFN-c),
tumor necrosis factor (TNF-a), and interleukin 1 beta (IL-1b) and
its function is part of the macrophage-mediated response to
infectious agents. It has reported that normal human melanocytes
will express iNOS following incubation with LPS, TNF-a, and
IFN-c, then high doses of NO can result in self-destroy of cultured
normal human melanocytes and pigment loss [12,13,14].
Moreover, NO is reported as a regulatory mediator involved in
the development of autoimmune disease [15] and Ivanova et al.
[14] also reported that NO can affect adherence of melanocyte
and cell matrix, inhibiting melanocyte proliferation, changing
melanocyte form and induced melanocyte death ultimately.
Therefore, it is conceivable that iNOS is involved in the
pathogenesis of vitiligo.
The human iNOS gene is located on the chromosome 17q11.2–
q12, has a genomic size of 48 kb, and encodes a protein of
131 kDa [16]. Among several single nucleotide polymorphisms
(SNPs) in iNOS that have been reported previously, the promoter
polymorphisms iNOS-1173 CRT and -954 GRC have been shown
to modify iNOS transcription and mRNA levels [17,18]. A C-to-T
transition at exon 16 was located only six amino acids N-
terminally from the deletion reported by Daff [19], and the amino
acid substitution (from serine to leucine) in exon 16 might be of
functional interest.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27077Considering the important role that iNOS plays in the
production of NO and, thus, in the pathogenesis of vitiligo, we
hypothesized that the functional polymorphisms in the iNOS gene
may be associated with the risk of vitiligo. However, to date, there
has been no research about the polymorphisms of iNOS gene in the
etiology of vitiligo. We genotyped the three reported functional
single nucleotide polymorphisms of the iNOS gene (i.e., -1173
CRT, -954 GRC, and Ex16+14 CRT) to test this hypothesis in




This study included 749 Han Chinese patients with vitiligo and
763 age- and sex-matched controls. Because genotype frequencies
can vary among ethnic groups, only Han Chinese patients (more
than 90% of population of China) and controls were included in
this analysis. All the patients had not subjected to any therapy in
recent 6 months. All the healthy subjects did not show clinical
evidence or family history of vitiligo or of any other autoimmune
disorder. Vitiligo was clinically characterized in patients as
segmental and non-segmental [20]. Segmental vitiligo was
diagnosed if the disease followed a dermatomal distribution.
Active vitiligo was defined as the appearance of new lesions or the
enlargement of existing lesions in the 3 months before presenta-
tion. The protocols used in the study were approved by the
Hospital’s Protection of Human Subjects Committee (Xijing
Hospital, Fourth Military Medical University, Clinical Ethics
Committee). We have obtained informed consent from all
participants involved in our study. This consent was written and
saved in our department.
Genotyping
Genomic DNA was extracted from cell pellets by using a blood
genomic DNA purification kit (Tiangen, Beijing, China). The
iNOS-954 GRC and Ex16+14 CRT polymorphisms were
determined using the PCR-RFLP method, whereas the iNOS-
1173 CRT polymorphism was carried out using MS-PCR.
Genomic DNA was prepared from venous blood samples using
a DNA extract kit (Tiangen, Beijing, China). DNA purity and
concentration were determined by spectrophotometric measure-
ment of absorbance at 260 and 280 nm. PCR was used to amplify
the fragments that contained the select iNOS polymorphic sites.
The primers of iNOS-954 GRC were as follows: 59- CATATG-
TATGGGAATACTGTATTTCAG -39 (forward) and 59- TCT-
GAACTAGTCACTTGAGG -39 (reverse), as previously reported
[18]. The Ex16+14 CRT was amplified with following primers:
59- CATATGTAAACCAACTTCCGTG -39 (forward) and 59-
GGCAGGGCTAGGAGTAGGAC -39 (reverse), as previously
reported [21]. The primers of iNOS-1173 CRT are as follows: 59-
GACAAGAAGGAAATGAGTGGACACAGGTAGCAAAGT-
GTTGAGAC -39 (MS-P2F), 59- GCATTTTTCCATCATAA-
AAGTAA -39 (MS-P3R) and 59- GTGGTAGCAAATGTTGG-
AAT -39 (MS-P4F), as previously reported [22].The amplified
PCR products for the iNOS-954 GRC and Ex16+14 CRT
polymorphisms were 573 bp and 219 bp, respectively. Then we
used BsaI and Tsp509I restriction enzymes (New England Biolabs,
Beverly, Mass) to delineate the iNOS-954 GRC and Ex16+14
CRT polymorphisms, respectively. Cuts by these enzymes resulted
in 573-bp and 446-bp fragments in the case of the iNOS-954 G
allele, 175-bp and 44-bp fragments in the case of the iNOSEx16+14
C allele. The amplified PCR products of the iNOS-1173 C and
iNOS-1173 T alleles were 131 and 102 bp, respectively. About
10% of the samples were randomly selected and genotyped again
with the same method to test the discrepancy rate, and the results
were 100% concordant. In addition, every genotype was
sequenced to confirm its authenticity.
Serum iNOS activity analysis
We used computer-generated random numbers to assign 89
vitiligo patients from experimental group and 89 normal samples
from control group for serum iNOS activity analysis. The
statistical analysis of the epidemiologic feature and genotype
frequency between the selected 89 vitiligo patients and experi-
mental group did not show significance. The unit of serum NOS
activity is defined as: one milliliter serum generates 1 nmol NO
per minute is defined as one unit of activity. NOS has three major
types: neuronal NOS (nNOS), endothelial NOS (eNOS) and
inducible (iNOS). nNOS’ and eNOS’ existence is depended on the
calcium and resided in the neuron and the endotheliocyte;
however, iNOS resided in the macrophage and its existence has
no relationship with the calcium. According to this principle, we
could type the NOS easily. Here, we used the NOS examining kit
(The first substation of Jiang Cheng bioengineering institute,
Nanking) to detect the serum iNOS activity in differential samples,
the experimental process was performed according to the
instruction manual and previously reported [23]. Briefly, under
the 530 nm wavelength, we first detected the absorbance of
differential samples with the chromatometry method, then
according the following formula to calculate the iNOS activity.
The calculating formula is: iNOS (U/mL)=(iNOS measuring
tube OD value – blank tube OD value)/coloration material
nanomole absorbancy index6(bulk volume of the reaction liquid/
sampling volume)6(1/optical path of the shade selection6reation
time)/1 000.
Statistical analysis
The chi-square test was used to evaluate the differences in
frequency distribution for the selected demographic variables,
including each allele and genotype of the iNOS polymorphisms and
the serum iNOS activity between the vitiligo cases and controls.
Unconditional univariate analyses and multivariate logistic
regression analyses were performed to obtain the crude and
adjusted odds ratios (ORs) for the risk of vitiligo as well as the 95%
confidence intervals (CIs). The multivariate adjustment included
age and gender. The D9 value for linkage disequilibrium between
the three iNOS polymorphisms and the haplotypes frequencies
were calculated by SHEsis (http://analysis.bio-x.cn/myAnalysis.
php) [24]. The genotype data for each polymorphism was further
stratified by subgroups of sex, stage, type, onset age, family history,
and with/without other autoimmune diseases. The interaction
between the three iNOS polymorphisms was evaluated by using
multivariate logistic regression models. Statistical significance was
established at a P value of 0.05. Two-side tests of statistical
significance were performed by using the SAS software (version
9.1; SAS Institute, Inc., Cary, North Carolina).
Results
Characteristics of the Study Population
The frequency distributions of selected characteristics of the
controls and vitiligo patients are summarized in table 1 (Table 1).
The age of the patients ranged from 2 to 95 years (24.9613.9,
mean6SD) and the controls are from 1 to 75 years (26.2613.7)
(P=0.703). The frequency distributions in men and women were
55.3 and 44.7%, respectively in the cases, and 54.1 and 45.9%,
respectively in the controls (P=0.675). Among the cases were 43
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patients and 623 (83.2%) active and 126 (16.8%) stable vitiligo
patients. One hundred and twenty eight (17%) vitiligo patients
were considered to have a family history and 28 (4.2%) cases have
other auto-immune diseases. Patients were considered to have
early onset vitiligo (n=384, 61.4%) if the age of onset was prior to
20 years old [25].
Association between iNOS Genotypes and the Risk of
Vitiligo
As shown in Table 2, the distribution of all genotypes among
controls was compatible with the Hardy-Weinberg equilibrium
(x
2: P=0.877 for iNOS-1173 CRT; P=0.133 for iNOS-954 GRC;
P=0.080 for iNOSEx16+14 CRT). The differences in iNOS-1173
and Ex16+14 genotyping distributions between vitiligo cases and
controls were not statistically significant (P=0.542 and P=0.736,
respectively). Similarly, the iNOS-1173 T allele and Ex16+14 T
allele did not differ significantly between cases and controls (12.6%
vs.11.4%, P=0.329 and 13.1% vs.15.5%, P=0.068, respectively).
However, the iNOS-954 variant C allele frequency was significantly
higher among cases than among controls (8.9% vs.6.7%,
P=0.028), and the frequency of the iNOS-954 (GC+CC) combined
genotype was also significantly higher in cases than in controls
(16.6% vs.12.6%, P=0.029).
When we used the iNOS-954 GG genotype as the reference
group, we found a statistically significant increased risk of vitiligo
was associated with the -954 combined (GC+CC) genotype
(adjusted OR=1.39; 95% CI=1.11–1.74). However, when
Table 1. Clinical characteristics of the 749 Chinese vitiligo patients and 763 healthy controls.
Vitiligo(N/%) (N=749) Healthy controls (n/%) (n=763)
Average age (year, mean6S.D.) 24.9613.9 26.2613.7
Number of female/male 335(0.45)/414(0.55) 350(0.46)/413(0.54)
Early onset/late onset 462(0.62)/287(0.38)
Active/stable 623(0.83)/126(0.17)
Nonsegmental/segmental 706(0.94)/43(0.06)
With/without family history 128(0.17)/621(0.83)
With/without other autoimmune diseases 28(0.04)/721(0.96)
doi:10.1371/journal.pone.0027077.t001
Table 2. Genotypic frequencies of iNOS polymorphisms in cases and controls and their associations with risk of vitiligo.
Genotypes Cases (N=749) Controls (n=763)
a





GG 625 83.4 667 87.4 1.00 0.087
GC 115 15.4 90 11.8 1.35(1.01–1.81)
CC 9 1.2 6 0.8 1.49(0.52–4.23)
GC+CC 124 16.6 96 12.6 1.36(1.02–1.81) 0.029
C allele 8.9 6.7 0.028
iNOS-1173
CC 574 76.6 599 78.5 1.00 0.542
CT 161 21.5 154 20.2 1.09(0.85–1.40)
TT 14 1.9 10 1.3 1.42(0.62–3.23)
CT+TT 597 79.7 637 83.5 1.11(0.87–1.41) 0.058
T allele 12.6 11.4 0.329
iNOSEx16+14
CC 571 76.2 569 74.6 1.00 0.736
CT 160 21.4 173 22.7 0.92(0.72–1.18)
TT 18 2.4 21 2.8 0.84(0.44–1.60)
CT+TT 178 23.7 194 25.4 0.91(0.72–1.16) 0.453
T allele 13.1 15.5 0.068
CI, confidence interval; OR, odds ratio.
aThe observed genotype frequencies among the controls were in agreement with the Hardy–Weinberg equilibrium (x
2: P=0.977 for iNOS-1173 CRT; P=0.133 for iNOS-
954 GRC; P=0.080 for iNOSEx16+14 CRT).
bORs were obtained from a multivariate logistic regression model with adjustment for age and sex.
cAdjustment for age and sex.
doi:10.1371/journal.pone.0027077.t002
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groups, no significant risk was associated with any other genotypes.
Stratification analysis of the iNOS Polymorphisms and
Known Risk Factors of Vitiligo
To investigate the effects of iNOS polymorphisms on vitiligo, we
performed an additional stratification analysis with the dichoto-
mized genotypes groups. We observed significant association with
iNOS-954 combined (GC+CC) genotype in subgroups that were
with active vitiligo (adjusted OR=1.35; 95% CI=1.01–1.82), that
were diagnosed with nonsegmental vitiligo (adjusted OR=1.36;
95% CI=1.02–1.82) and that had no other autoimmune diseases
(adjusted OR=1.39; 95% CI=1.04–1.85) (Table 3). We also
performed the stratified analysis for iNOS-1173 and Ex16+14, but
no statistically significant results were found (data not shown).
Association between iNOS Haplotypes and the Risk of
Vitiligo
The Linkage Disequilibrium tests showed that the three
polymorphisms of iNOS gene were in Linkage Disequilibrium
(D9=0.897, P,0.01 for iNOS-1173 and -954; D9=0.613, P,0.01
for iNOS-1173 and Ex16+14; D9=0.392, P,0.01 for iNOS -954
and Ex16+14). There were eight possible iNOS haplotypes derived
from the known genotypes, whereas those frequency,0.03 were
ignored in analysis (i.e. C-1173C-954TEx16+14, T-1173G-954TEx16+14,
T-1173C-954TEx16+14, T-1173C-954CEx16+14). As shown in Table 4, the
iNOS C-1173C-954CEx16+14 haplotype frequency was significantly
different between vitiligo cases and controls (7.3% vs.5.3%,
respectively; P=0.016). Moreover, the haplotype C-1173
C-954CEx16+14 was associated with a significantly increased risk of
vitiligo (adjusted OR=1.44, 95% CI=1.01–1.74).
Table 3. Stratification analysis of the iNOS -954 genotypes and vitiligo risk by selected variables.





Total 625/667 48.4/51.6 124/96 56.4/43.6 1.36 (1.02–1.81) 0.029
Onset age(years)
#20 384/667 61.4/- 78/96 62.9/- 1.08 (0.76–1.53) 0.087
.20 241/667 38.6/- 46/96 37.1/- 1.47 (0.97–2.22) 0.146
Sex
Male 345/362 55.2/54.3 69/51 55.6/53.1 1.39 (0.93–2.05) 0.078
Female 280/305 44.8/45.7 55/45 44.4/46.9 1.32 (0.86–2.02) 0.187
Stage
Stable 105/667 16.8/- 21/96 16.9/- 1.32 (0.79–2.22) 0.209
Active 520/667 83.2/- 103/96 83.1/- 1.35 (1.00–1.82) 0.037
Type
Nonsegmental 589/667 94.2/- 117/96 94.4/- 1.36 (1.02–1.82) 0.030
Segmental 36/667 5.8/- 7/96 5.6/- 1.09 (0.46–2.55) 0.480
Family history
Yes 105/667 16.8/- 23/96 18.5/- 1.42 (0.86–2.35) 0.097
No 520/667 83.2/- 101/96 81.5/- 1.33 (0.98–1.80) 0.051
Autoimmune diseases
With 26/667 4.2/- 2/96 1.6/- 0.57 (0.13–2.44) 0.391
Without 599/667 95.8/- 122/96 98.4/- 1.39 (1.04–1.85) 0.018
aOdds ratios (ORs) were obtained from a multivariate logistic regression model with adjustment for age and sex. 95% CI, 95% confidence interval.
bAdjustment for age and sex.
doi:10.1371/journal.pone.0027077.t003





C-1173G-954CEx16+14 1021(68.1) 1060(69.4) 0.083 0.772 0.98 (0.83–1.14)
C-1173G-954TEx16+14 172(11.5) 200(13.1) 1.455 0.228 0.88 (0.70–1.09)
T-1173G-954CEx16+14 155(10.3) 163(10.7) 0.032 0.859 0.98 (0.78–1.24)
C-1173C-954CEx16+14 109(7.3) 80(5.3) 5.753 0.016 1.44 (1.01–1.74)
aFrequency,0.03 (i.e., C-1173C-954TEx16+14, T-1173G-954TEx16+14, T-1173C-954TEx16+14, T-1173C-954CEx16+14) in both control & case has been ignored in analysis.
doi:10.1371/journal.pone.0027077.t004
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Association between iNOS Combined Genotypes and
Risk of Vitiligo
Considering the potential joint effects of the three polymor-
phisms of iNOS, we further evaluated the interaction among the
iNOS polymorphisms and the association between the combined
genotypes of iNOS-1173, -954, and Ex16+14 and the risk of
vitiligo, with the multivariate logistic regression models. Firstly, we
analyzed any two of the three polymorphisms. We found the
interaction between iNOS-1173, -954, and Ex16+14 was not
statistically significant (P=0.311, P=0.150, P=0.202, respective-
ly). We next analyzed the combined genotypes of the three iNOS
polymorphisms, but we found no statistically significant relation-
ship between any two of the three polymorphisms or among the
three iNOS polymorphisms (data not shown).
Association between Serum iNOS Activity and the Risk of
Vitiligo
In order to analysis the serum iNOS activity and risk of vitiligo,
we compared the serum iNOS activity in 89 vitiligo patients with
the 89 normal control samples. We found the serum iNOS activity
in vitiligo patients’ group is significantly higher than that in the
normal control group (15.4063.98 U/ml vs.13.2962.45 U/ml;
u=6.58, P,0.01) (Figure 1A). Furthermore, to examine the
relationship between the iNOS-954 gene polymorphism and the
serum iNOS activity in vitiligo patients, we also studied the serum
iNOS activity in differential genotype of iNOS-954. Because the
number of risk genotype CC group is very small (3 samples), we
only examined the serum iNOS activity in iNOS-954 protective
genotype GG group with the risk genotype (GC+CC) group. Our
results showed that compared with the iNOS-954 protective
genotype GG group, the risk genotype (GC+CC) group has the
higher serum iNOS activity (16.8764.20 U/ml vs.13.8363.56 U/
ml; t=7.48, P,0.01) (Figure 1B).
Logistic Regression Analysis of iNOS Activity in Vitiligo
Patients and Controls
As shown in Table 5, we performed a logistic regression analysis
of serum iNOS activity in vitiligo patients and controls. When we
dichotomized the iNOS activity by the median activity of the
controls, we found an increased risk for vitiligo was associated with
the higher activity (adjusted OR=2.14, 95% CI=1.88–2.45).
According to the iNOS activity of controls, we further divided the
iNOS activity into three decile. When we used efficient (lower
tertile) activity as the reference, the suboptimal (upper tertile)
activity was associated with an increased risk of vitiligo (adjusted
OR=1.64, 95% CI=1.35–1.86; Ptrend,0.001).
Risk of Vitiligo Associated with iNOS-954 GRC Genotypes
by iNOS Activity
Furthermore, we estimated the risk of vitiligo associated with
iNOS-954 genotypes by iNOS activity (Table 6). We divided iNOS-
954 GRC genotypes into two categories, 0 risk genotype (-954 GG)
and 1–2 risk genotypes (-954 GC or -954 CC). When the -954 GG
was used as the reference, the individuals with 1–2 risk genotypes
(-954 GC or -954 CC) and higher iNOS activity ($14.05) showed
more increased risk of vitiligo (adjusted OR=4.53, 95%
CI=2.71–7.44). When we divided the iNOS activity into three
decile according to the controls’ activity, the -954 GC or CC
genotype combined higher iNOS activity was associated with
increased risk of vitiligo ($14.83, adjusted OR=2.40, 95%
CI=1.35–4.03).
Discussion
In this hospital-based case-control study, we investigated the
associations of the iNOS-1173 CRT, -954 GRC, and
Ex16+14CRT polymorphisms with risk of vitiligo in Han Chinese
populations. We found that compared to the iNOS-954 GG
genotype, the iNOS-954 combined (GC+CC) genotypes were
associated with an increased risk of vitiligo. The association was
more pronounced in patients with active vitiligo, nonsegmental
vitiligo and vitiligo without other autoimmune disorders. This
suggests that iNOS-954 gene polymorphism may have a greater
effect on these subgroups. The differences maybe due to the
reduction in the number of observations in some strata or may
reflect true susceptible subgroups. Further exploration is needed to
determine whether the effects found here are an aberration, and
what the exact mechanisms underlying such effects are.
Compared with the previously published data, the iNO-
SEx16+14 T allele frequencies were similar to the frequencies in
other Chinese controls and Japanese [26,27]. However, we found
the iNOS-954 C allele frequency was lower in Han Chinese than in
Figure 1. Serum iNOS activity and correlations to vitiligo
genetype. (A) The serum iNOS activity in vitiligo patients’ group is
significantly higher than that in the normal control group (P,0.01). (B)
Compared with the iNOS–954 protective genotype GG group, the risk
genotype (GC+CC) group has the higher serum iNOS activity (P,0.01).
doi:10.1371/journal.pone.0027077.g001
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iNOS-954 polymorphism vary with ethnicity.
The iNOS-954 polymorphism is located in the iNOS promoter
region, which could be an activator of gene expression [22]. INOS-
954 C allele, but not the iNOS-954 G allele, may have a higher
affinity to a DNA binding protein, thus, transcriptional activity
and mRNA levels were increased in the iNOS-954 C allele. Then
the NOS activity and NO production were increased. Our result
certified iNOS-954 C allele can increase iNOS activity.
To the best of our knowledge, this is the first study on the
association between the iNOS polymorphisms and vitiligo in the
Han Chinese population. An early event in the onset of vitiligo
appears to involve the overproduction of tetrahydrobiopterin,
which leads to the accumulation of a potent inhibitor of melanin
biosynthesis [28]. The synthesis of tetrahydrobiopterin is cytokine
induced and it is an essential cofactor in the enzymatic activity of
iNOS [29]. LPS/cytokines can stimulate normal human melano-
cytes express iNOS. This enzyme might therefore be involved in
the altered melanin production associated with post-inflammatory
hypopigmentation [30]. In vitiligo, the increase of iNOS activity
caused by overexpression of the tetrahydrobiopterin or LPS/
cytokines can produce plenty of NO generation. NO has been
reported to contribute to the loss of melanocytes in vitiligo by
reducing de novo attachment of melanocytes to the extracellular
matrix components. Moreover, increased iNOS activity induces
NO production and O2
2, which result in the accumulation of
hydrogen peroxide. High of hydrogen peroxide can lead to
melanocytes destruct and depigmentation ultimately [31]. The
increased NOS activity had been confirmed in vitiligo affected/
nonaffected melanocytes and keranocytes. Our study also
confirmed that the increased iNOS activity was related with the
onset of vitiligo indirectly. However, the specific mechanisms of
iNOS involved in the pathogenesis of vitiligo still need further
research.
In summary, we provide evidence that iNOS polymorphisms
may influence the risk and clinical progression of vitiligo in Han
Chinese populations. A statistically significantly increased risk of
vitiligo was associated with the iNOS-954 (GC+CC) genotype
compared with the -954 GG genotype, which was more
pronounced among vitiligo patients with the following character-
istics: non-segmental, active vitiligo and without other autoim-
mune diseases. But no evident risk was associated with the iNOS-
1173 and Ex16+14 polymorphisms. Furthermore, we found the
serum iNOS activity was significantly higher in vitiligo and was
increased in iNOS-954 combined genotype (GC+CC) compared
with -954 GG genotype. Nevertheless, better-designed and larger
Table 6. Risk of vitiligo associated with iNOS-954 GRC genotypes by iNOS activity.
Activity iNOS-954 GRC (case/control)
0 risk genotype OR(95% CI)
a 1–2 risk genotype OR(95% CI)
a
By median
,14.05 18/50 1.00 6/12 0.81(0.25–2.68)
$14.05 45/22 1.17(0.33–1.62) 20/5 4.53(2.71–7.44)
By tertile
#13.17 11/38 1.00 2/6 0.41(0.14–2.76)
13.17–14.83 19/22 1.02(0.84–1.32) 10/5 1.07(0.74–1.80)
$14.83 33/12 1.61(0.21–2.06) 14/4 2.40(1.35–4.03)
Trend test - - - P
b,0.001
aOdds ratios (ORs) were obtained from a logistic regression model with adjustment for age and sex; 95% CI, 95% confidence interval.
bAdjusted for age and sex.
doi:10.1371/journal.pone.0027077.t006
Table 5. Logistic regression analysis of iNOS activity in vitiligo patients and controls.




,14.05 28 31.4 48 53.9 1.00
$14.05 61 68.6 41 46.1 2.14(1.88–2.45)
By tertile
#13.17 15 16.9 32 36.0 1.00
13.17–14.83 33 37.1 35 39.3 1.14(0.88–1.36)
$14.83 41 46.0 22 24.7 1.64(1.35–1.86)
Trend test - - - - P
b,0.001
aOdds ratios (ORs) were obtained from a logistic regression model with adjustment for age and sex; 95% CI, 95% confidence interval.
bAdjusted for age and sex.
doi:10.1371/journal.pone.0027077.t005
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detailed environmental exposure data are necessary to further test
potential gene-environment interactions.
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